KHK4563 + KHK4563 + KHK4563 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Uncontrolled and Suspected Eosinophilic Asthma
Conditions
Uncontrolled and Suspected Eosinophilic Asthma
Trial Timeline
Aug 1, 2011 → Oct 1, 2013
NCT ID
NCT01412736About KHK4563 + KHK4563 + KHK4563 + Placebo
KHK4563 + KHK4563 + KHK4563 + Placebo is a phase 2 stage product being developed by Kyowa Kirin for Uncontrolled and Suspected Eosinophilic Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT01412736. Target conditions include Uncontrolled and Suspected Eosinophilic Asthma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01412736 | Phase 2 | Completed |
Competing Products
17 competing products in Uncontrolled and Suspected Eosinophilic Asthma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| HR17031 injection + insulin glargine | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Baxdrostat + Placebo | AstraZeneca | Phase 3 | 77 |
| Tralokinumab | AstraZeneca | Phase 3 | 77 |
| Baxdrostat + Placebo | AstraZeneca | Phase 3 | 77 |
| Benralizumab | AstraZeneca | Phase 3 | 77 |
| Baxdrostat + Placebo | AstraZeneca | Phase 2 | 52 |
| Experimental: Tralokinumab | AstraZeneca | Phase 3 | 77 |
| Phase IIb formulation + Putative phase III formulation + Slow dissolution variant 1 + Slow dissolution variant 2 + Test treatment E | AstraZeneca | Phase 1 | 33 |
| CIN-107 + Placebo | AstraZeneca | Phase 2 | 52 |
| Pegloticase + Methotrexate (MTX) | Amgen | Approved | 84 |
| Pegloticase | Amgen | Approved | 84 |
| Pegloticase + Methotrexate | Amgen | Phase 3 | 76 |
| Pegloticase + Methotrexate (MTX) | Amgen | Approved | 84 |
| Pegloticase with MTX | Amgen | Approved | 84 |
| abrocitinib | Pfizer | Pre-clinical | 22 |
| REGN5381 + Placebo | Regeneron Pharmaceuticals | Phase 2 | 51 |
| SAL0140 + SAL0140 placebo | Shenzhen Salubris Pharmaceuticals | Phase 1 | 32 |